SCHEMBL30474327

SCHEMBL30474327

CC(C)(C)OC(=O)N1CCc2ccc(C(=O)O)nc2C1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ESR2 Q92731 1/20 0.55
▸ NR1H2 P55055 2/20 0.54
▸ MAPT P10636 2/20 0.46
▸ PARP1 P09874 1/20 0.44
▸ TNKS2 Q9H2K2 1/20 0.44
▸ PARP2 Q9UGN5 1/20 0.44
▸ ADORA1 P30542 1/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ GRM5 P41594 2/20 0.41
▸ GPR119 Q8TDV5 2/20 0.40
▸ GRAMD1A Q96CP6 1/20 0.40
▸ DDB1 Q16531 1/20 0.39
▸ CRBN Q96SW2 1/20 0.39
▸ CKS1B P61024 1/20 0.38
▸ SKP1 P63208 1/20 0.38
▸ SKP2 Q13309 1/20 0.38
▸ IGF1R P08069 1/20 0.38
▸ GRM1 Q13255 1/20 0.38
▸ P2RX3 P56373 1/20 0.38
▸ MTOR P42345 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29676623 0.90 ESR2 (0.55) ESR2NR1H2MAPTPARP1TNKS2
SCHEMBL3985607 0.90 ESR2 (0.55) ESR2NR1H2MAPTPARP1TNKS2
SCHEMBL31185941 0.88 ESR2 (0.46) ESR2NR1H2MAPTMAPK1GPR119
SCHEMBL22981578 0.88 ESR2 (0.53) ESR2NR1H2MAPTPARP1TNKS2
SCHEMBL24722485 0.85 ESR2 (0.50) ESR2NR1H2MAPTPARP1TNKS2
SCHEMBL10313013 0.85 ESR2 (0.57) ESR2NR1H2MAPTPARP1TNKS2
SCHEMBL21041656 0.85 ESR2 (0.61) ESR2NR1H2MAPTPARP1TNKS2
SCHEMBL30013710 0.85 ESR2 (0.61) ESR2NR1H2MAPTPARP1TNKS2
SCHEMBL16691229 0.84 NR1H2 (0.62) ESR2NR1H2MAPTPARP1TNKS2
SCHEMBL29712352 0.84 ESR2 (0.60) ESR2NR1H2MAPTPARP1TNKS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250109148-A1 HETEROCYCLIC GLP-1 AGONISTS SHANGHAI SHOUTI BIOTECHNOLOGY CO., LTD. (CN) 2025-04-03 — — US disclosed
CN-119343339-A Heterocyclic GLP-1 agonists 加舒布鲁姆生物公司 2025-01-21 — — CN disclosed
EP-4469444-A1 HETEROCYCLIC GLP-1 AGONISTS Gasherbrum Bio, Inc. (US) 2024-12-04 — — EP disclosed
WO-2023138684-A1 HETEROCYCLIC GLP-1 AGONISTS GASHERBRUM BIO , INC. (US) 2023-07-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250109148-A1 HETEROCYCLIC GLP-1 AGONISTS GLP1R, GIPR, GCGR ESR2 447/4885NR1H2 456/4885MAPT 3323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback